Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025)
Immatics' (IMTX) quarterly Net Income towards Common Stockholders came in at -$46.2 million in Q4 2025, down 188.04% year-on-year from $52.5 million in Q4 2024, and up 22.23% quarter-over-quarter from -$59.4 million in Q3 2025.
Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Immatics has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$46.2 million for Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$46.2 million, down 188.04% year-over-year; the trailing twelve-month figure through Dec 2025 was -$229.4 million (down 1520.9% YoY), and the FY2025 annual result was -$221.9 million, down 1464.84% from the prior year.
- Net Income towards Common Stockholders came in at -$46.2 million for Q4 2025 at Immatics, up from -$59.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $96.1 million in Q1 2022 to a low of -$81.9 million in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$23.4 million (2023), against an average of -$18.0 million.
- Across the five-year window, Net Income towards Common Stockholders jumped 449.38% in 2022 and plunged 1232.27% in 2023, its largest moves.
- Immatics' Net Income towards Common Stockholders stood at -$19.2 million in 2021, then soared by 111.78% to $2.3 million in 2022, then plunged by 1232.27% to -$25.6 million in 2023, then jumped by 304.83% to $52.5 million in 2024, then tumbled by 188.04% to -$46.2 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$46.2 million (Q4 2025), -$59.4 million (Q3 2025), and -$81.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | -46.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46.18 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -41.92 Mn |
| Dec 31, 2024 | 52.46 Mn |
| Sep 30, 2024 | -13.62 Mn |
| Jun 30, 2024 | -19.38 Mn |
| Mar 31, 2024 | -3.32 Mn |
| Dec 31, 2023 | -25.61 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |